Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295881 | 1.00 | CYP2D6 (0.45) | CYP2D6LTA4HCHRM2HTR1ADRD3 | |
| SCHEMBL83704 | 1.00 | CYP2D6 (0.45) | CYP2D6LTA4HCHRM2HTR1ADRD3 | |
| SCHEMBL2299681 | 1.00 | CYP2D6 (0.45) | CYP2D6LTA4HCHRM2HTR1ADRD3 | |
| SCHEMBL2295242 | 1.00 | CYP2D6 (0.45) | CYP2D6LTA4HCHRM2HTR1ADRD3 | |
| SCHEMBL4489117 | 0.95 | HTR1A (0.45) | CYP2D6LTA4HCHRM2HTR1ADRD3 | |
| SCHEMBL2115070 | 0.88 | CYP2D6 (0.47) | CYP2D6LTA4HCCR5MC4ROPRM1 | |
| SCHEMBL2291288 | 0.87 | CYP2D6 (0.45) | CYP2D6LTA4HCHRM2HTR1ADRD3 | |
| SCHEMBL2295583 | 0.87 | CHRM2 (0.45) | CYP2D6LTA4HCHRM2HTR1ADRD3 | |
| SCHEMBL2294555 | 0.87 | CHRM2 (0.45) | CYP2D6LTA4HCHRM2HTR1ADRD3 | |
| SCHEMBL2290318 | 0.87 | CYP2D6 (0.45) | CYP2D6LTA4HCHRM2HTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| EP-2406254-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-01-18 | — | — | EP | disclosed |
| EP-2266969-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2266979-A1 | 2-morpholino-4-pyrimidone compounds | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-29 | — | — | EP | disclosed |
| EP-2261224-A2 | 6-(Pyridinyl)-4-pyrimidone derivatives as tau protein kinase 1 inhibitors | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-12-15 | — | — | EP | disclosed |
| WO-2010104193-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-16 | — | — | WO | disclosed |
| EP-1789414-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006028290-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | HRH4, HNMT, CYP3A4 | CYP2D6 25/4885LTA4H 3620/4885CHRM2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.